Heme oxygenase-1 (HO-1) is an enzyme with potent immunoregulatory capacity. To evaluate the effect of HO-1 on autoimmune diabetes, female NOD mice at 9 weeks of age received a single intravenous injection of a recombinant adeno-associated virus bearing HO-1 gene (AAV-HO-1; 0.5 x 10 10
INTRODUCTION
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the progressive destruction of pancreatic insulin-producing β-cells (1) . Studies on NOD mice, which spontaneously develop T1D with features similar to the human disease, have demonstrated that the disease is initiated by infiltration of 2 antigen-presenting cells, particularly dendritic cells (DCs), into pancreatic islets followed by recruitment of T and B lymphocytes (2, 3) . In these mice, insulitis appears around 3-4 weeks of age and is well established by 10 weeks without clinical symptoms. The progression to overt diabetes occurs in 80% of female mice by 30 weeks of age. Evidence suggests that β-cell destruction is mediated primarily by a skewed type 1 T helper cell (Th1)-mediated response and the production of proinflammatory cytokines (4) . How the biased Th1 phenotype and the progression to destructive insulitis are regulated over the course of T1D development is not fully understood. Nevertheless, it is well documented that full activation of naive T cells requires presentation of antigen in the context of the MHC II complex and costimulatory signals from mature DCs (5-7). DCs from NOD mice have been shown to exhibit enhanced APC function and abnormally high costimulatory and Th1-inducing abilities (8) (9) (10) .
Furthermore, increasing evidence suggests that the autoimmune process is caused by the failure of immunosuppressive mechanisms (11-13). Heme oxygenase-1 (HO-1) is a stress-response enzyme that catalyzes the degradation of heme to free iron, carbon monoxide (CO), and biliverdin in mammalian cells (16, 17) . Over the past few years, accumulated evidence has supported an immunoregulatory function for HO-1. It has been shown that HO-1 3 overexpression prevents graft rejection in organ transplantation (18) . HO-1 and CO exhibit potent antiproliferative effects on T cells, and HO-1 promotes activation-induced cell death of alloreactive T cells (19) (20) (21) (22) . A study on HO-1-deficient mice revealed that the absence of HO-1 correlates with a Th1-weighted shift in cytokine responses, suggesting a pivotal role for HO-1 in regulating the immune response (23 (24, 25) . A recent study revealed that HO-1 is expressed in immature DCs, and HO-1 expression decreases with DC maturation (26) . Induction of HO-1 expression inhibits DC maturation. These findings support the functional importance of HO-1 in immune regulation.
The aforementioned properties of HO-1 provoked our interest in investigating the impact of HO-1 on the development of T1D in NOD mice. To determine the effect of HO-1 on the progression to overt diabetes in prediabetic mice with insulitis, we performed systemic gene transfer of HO-1 mediated by adeno-associated virus (AAV) in female NOD mice at 9 weeks of age. The effect of HO-1 gene transduction on the onset of diabetes was then assessed over a 15-week period. Our results clearly showed that systemic HO-1 expression suppressed the progression of insulitis and delayed the onset of hyperglycemia.
RESEARCH DESIGN AND METHODS
Construction of recombinant adenoassociated virus vector. We used the 4 AAV helper-free system from Stratagene (La Jolla, CA, USA) for vector construction. Mouse HO-1 cDNA was obtained by RT-PCR of RNA isolated from heme-treated murine J774 cells and subcloned into the pCMV-MCS plasmid. Recombinant AAV vector was then prepared according to the manufacturer's instructions. The large-scale production and purification of AAV virus were conducted using heparin affinity chromatography as described by Clark et al. (27) . The recombinant AAV particles were quantified by real time PCR using a PE-Applied Biosystems Prism 7700 sequence detector (Foster City, CA, USA) and fluorescent probe sets. The primers and probe used for quantification of AAV-HO-1 were as follows: HO-1 5'-primer, 5'-AGGTGATGCTGACAGAGGAACAC-3'; HO-1 3'-primer, 5'-TAGCAGGCCTCTGACGAAGTG-3'; HO-1 probe, 5'-6-carboxy-fluorescein-AAGACCAGAGTCCCTCACAGATGG CG-6-carboxy-tetramethyl-rhodamine-3'.
Animals. Female NOD and NOD.scid mice were purchased from Jackson Laboratory, and kept in specific pathogen-free conditions. Female NOD mice at 9 weeks of age were subjected to retro-orbital plexus injection of saline or the indicated amounts of AAV-HO-1 in 50 µl saline. Some NOD mice at 8-9 weeks of age received two intraperitoneal injections of cyclophosphamide (200 mg/kg body weight) with one-week interval to facilitate the onset of diabetes. To test the effect of CO, animals were exposed to 250 ppm CO gas as described previously (28) for 2 h twice per week. Animals were monitored twice per week for hyperglycemia as defined by two consecutive nonfasting blood glucose levels > 240 mg/dl. Mice were sacrificed at 24 weeks of age. All animal procedures were approved by the institutional animal care and utilization committee of Academia Sinica, Taipei, Taiwan. Cytokine measurements. Cytokines IL-2, IL-4, IL-10, and IFN-γ were measured by ELISA kits (R&D Systems).
Histopathology. The pancreas was removed, fixed in Bouin's solution (Sigma) for 16 h, embedded in paraffin, and sectioned at 5 µm. Sections were hematoxylin/eosin stained and evaluated on a blinded basis by two individuals using a 6 scoring criteria described by others (29) : stage 0 = normal islet, stage 1 = periinsulitis, stage 2 = insulitis in less than 50% of the islet, stage 3 = insulitis in greater than 50% of the islet. At least 20 islets from each pancreas were examined.
Immunohistochemistry. Sections were deparaffinized, rehydrated, and pretreated with target retrieval solution Western blot analysis. Tissues were homogenized in lysis buffer containing 25 mM Tris-HCl, pH 7.9, 1% Triton X-100, 10 mM EDTA, 1 mM sodium vanadate, 1 mM PMSF, and 1 µg/ml leupeptin. After centrifugation at 14,000 rpm for 30 min, the supernatant was removed, and protein concentration was determined by Bio-Rad protein assay. An equal amount of protein (50 µg) from each sample was separated by SDS-PAGE and transblotted onto nitrocellulose membranes. After blocking for 12 h with 5% nonfat milk in PBST, membranes were incubated with rabbit anti-HO-1 antibody (Stressgen), rabbit anti-HO-2 antibody (Santa Cruz), or rabbit anti-GAPDH antibody (Santa Cruz) for 1 h at 37 o C. After three washes with PBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 1 h. 7
Antigen was then detected using the ECL system. HO activity measurement. Tissues were homogenized in ice-cold 0.1M potassium phosphate buffer pH7.4 containing 1 mM EDTA and 0.5 mM PMSF, and Statistical analysis. Data were presented as mean ± SD and analyzed using the Mann-Whitney-Wilcoxon test. Hyperglycemia frequencies and survival rates were analyzed by the MantelHaenszel Chi-square test. P < 0.05 was considered statistically significant.
RESULTS
Effect of AAV-mediated systemic HO-1 transduction on type 1 diabetes in NOD mice. The expression levels of HO-1 and HO-2 and the net HO activity in NOD mice were first examined. Western blot analysis revealed no significant difference in the expression levels of HO-1 or HO-2 in lung, pancreas and liver between young (10 weeks) and old (24 weeks) mice (Fig.1A & B) . However, the HO activities measured in indicated tissues appeared to be lower in old NOD mice 8 compared to young counterparts (Fig.1C) . In order to evaluate the potential effect of HO-1 on T1D development, we constructed a recombinant AAV vector carrying mouse HO-1 gene for the in vivo gene transfer in NOD mice. AAVmediated transgene expression was first confirmed in HT1080 cells (data not shown). To assess the effect of HO-1 on T1D, 9-week-old female NOD mice received saline or various doses of AAV-HO-1 via retro-orbital plexus injection. The incidence of hyperglycemia in each group was examined for 15 weeks. As shown in Fig. 2A , 10% of the salinetreated control mice developed hyperglycemia in the following 1-3 weeks. In contrast, the onset of diabetes was substantially delayed in mice receiving AAV-HO-1. The salutary effect of AAV-HO-1 was dose-dependent, and 85% of mice receiving the highest dose of AAV-HO-1 (2.5 x 10 10 virus particles/mouse) remained normoglycemic at the time of sacrifice (P < 0.001 vs control group). Histological assessment of pancreatic sections from the animals revealed that the extent of insulitis was inversely correlated with the dose of AAV-HO-1 received (Fig. 2C) . In contrast to the control group in which only about 15% of the examined islets were devoid of lymphocyte infiltration, over 50% of the examined islets in the group treated with the highest dose of AAV-HO-1 were normal (P < 0.01 vs control group). To confirm that this protective effect resulted from sustained transgene expression, Western blot analysis was performed to examine HO-1 expression in various tissues 15 weeks after gene delivery. As shown in Fig. 3A & B, the levels of HO-1 protein in liver and spleen, which express high basal levels of HO-1, were not significantly enhanced by AAV-HO-1 administration. In contrast, HO-1 expression in lung, heart, and pancreas was significantly higher in mice receiving AAV-HO-1 (2.5 x 10 10 virus particles/mouse) compared to control counterparts. Likewise, HO activities determined in these tissues were also higher in AAV-HO-1-treated mice (Fig.3C) .
When immunostaining pancreatic sections, it was experiment was performed with 9 noted that HO-1 was primarily expressed in ß-cells of islets and was much prominent in mice receiving AAV-HO-1 (Fig.3D) . Together, these results support an inverse association between HO-1 expression and the onset of autoimmune diabetes in NOD mice.
Effect of HO-1 transduction on diabetogenic properties of T lymphocytes. To examine whether HO-1 expression affects the balance of Th1/Th2 responses, we measured Th1 and Th2 cytokines in serum samples and in media from Con Aactivated splenocytes isolated from surviving animals 15 weeks after saline or AAV-HO-1 (2.5 x10 10 particles) administration. As shown in Fig. 4A , significant decreases in serum levels of IL-2 and IFN-γ were observed in mice receiving AAV-HO-1. However, the levels of IL-4 and IL-10 were not significantly different between the salineand AAV-HO-1-treated groups. Likewise, the production of IL-2 and IFN-γ, but not of IL-4 and IL-10, by activated splenocytes was substantially lower in AAV-HO-1-treated mice (Fig. 4B) . To further confirm that HO-1 overexpression reduced the diabetogenicity of lymphocytes, an adoptive transfer experiment was performed in female NOD.scid mice. Splenocytes isolated from 24-week-old NOD mice with or without AAV-HO-1 treatment for 15 weeks were transferred into 5-week-old NOD.scid mice. Results showed that 9 of 10 mice receiving splenocytes from control donors became diabetic by 4 weeks after transfer, whereas the onset of diabetes was significantly delayed in recipients receiving splenocytes from AAV-HO-1-treated donors (P < 0.05) (Fig. 4C) .
Effect (Fig. 5B & C) .
Effect of CO exposure on type 1 diabetes. To determine whether CO, a byproduct of heme degradation, has a role in HO-1-mediated T1D protection, we exposed 9-week old NOD mice to a low dose of CO gas (250 ppm for 2 h) twice per week. As shown in Fig. 6A , CO treatment for a 15-week period did not significantly affect the expression levels of HO-1 in tissues examined. However, the incidence of diabetes in the COtreated group was significantly reduced compared with that of the control group (P < 0.001) (Fig. 6B) . Consistently, insulitis was less severe in CO-treated animals (Fig.6C) . In contrast to control mice in which only about 12 % of the examined islets were normal, about 40% of examined islets were normal in COtreated mice (P < 0.01 vs control group). To examine whether CO treatment also affects the Th1/Th2 response, cytokine expression in ConA-activated splenocytes isolated from control and CO-treated mice was assessed. As shown in Fig. 7 , the 11 levels of IL-2 and IFN-γ, but not of IL-4 and IL-10, were significantly lower in the CO-treated group compared to the control group. To further explore whether CO exerts protective effect on mice developing overt diabetes, NOD mice at age of 8-9 weeks received two intraperitoneal injections of cyclophosphamide (200 mg/kg body weight) to accelerate the onset of diabetes. Fifty percent of mice became diabetic within 3 weeks after the first injection of cyclophosphamide (data not shown). Mice with diabetes onset were either left untreated or treated with CO gas as described above beginning at day 3 after the disease onset (day 0) twice per week . It was found that CO treatment did not affect the hyperglycemia of diabetic mice (data not shown). However, CO significantly prolonged the survival of these animals (Fig.8) . In contrast to the untreated group in which 50% of the animals died at the first week after diabetes onset, all CO-treated animals were still alive at 6 weeks after the disease onset (P < 0.05 vs control group).
DISCUSSION
Decreased HO-1 expression has been shown in human patients with diabetes (30, 31) . Studies on experimental diabetes also revealed lower levels of HO-1 expression and HO activity in streptozotocin-induced diabetic rats compared to non-diabetic controls (32, 33) . In the present study, we did not observe significant changes in HO-1 and HO-2 protein expression along with aging process in NOD mice. However, a significant reduction in net HO activity was noticed in old NOD mice. This finding appears to be similar to a recent report showing that hyperglycermia did not affect HO-1 and HO-2 expression, but caused a decrease in HO-1 activity (33).
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It is conceivable that hyperglycermia developed in old NOD mice may have an impact on HO activity. Earlier studies by others have demonstrated that HO-1 overexpression can attenuate vascular endothelial damage and prevent cardiac ischemia/reperfusion injury in experimental diabetes (32, (34) (35) (36) . Furthermore, overexpression of HO-1 in islets provided protection from apoptosis and increased allograft survival (37) (38) (39) (40) An influence of HO-1 on the Th1/Th2 cytokine profile has also been reported in a study of liver allografts after HO-1 gene transfer (41) . A recent study on HO-1-deficient mice revealed a profound Th1 response following T cell stimulation (23) . The preferential suppression of Th1
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effector cell function by HO-1 suggests that HO-1 has a beneficial effect in various diseases involving the Th1-mediated immune response. Because destructive insulitis is closely associated with Th1 cell activation and Th1-type cytokine production, it is apparent that HO-1 suppresses T1D in NOD mice by influencing the diabetogenicity of T cells. HO-1 is an endoplasmic reticulumanchored protein, and its protective functions are primarily mediated through its reaction byproducts (16, 17) . Recently, studies have shown that both CO and bilirubin can prevent endothelial cell sloughing and prolong the survival of allogeneic islets in T1D likely through different mechanisms (33, 47, 48) . In the present study, we specifically assessed the potential role of CO in HO-1-mediated T1D protection in NOD mice. Animals were subjected to a 2-h exposure of low dose CO twice per week for a period of 15 weeks. We admit that this treatment may not exactly resemble the same situation in AAV-HO-1-treated mice in which CO was constantly produced by HO-1 in situ. Nevertheless, it was interesting to note that the prediabetic mice subjected to the periodic CO treatment had a significantly lower incidence of diabetes compared to the untreated control mice. Similar to what we observed in the AAV-HO-1-treated mice, Th1 cytokines produced by activated splenocytes were markedly reduced in the CO-treated group. Previous 15 mediated through studies on various disease settings in animals have revealed multiple cellular mechanisms underlying the protections conferred by CO inhalation. For example, CO has been shown to activate heme-containing soluble guanylyl cyclase to increase cellular cGMP level or modulate p38 kinase-mediated signaling transduction (17) . Recently, there are reports showing that CO treatment can protect animals against liver failure and chronic colitis through induction of HO-1 expression (49,50). We did not observe changes in level of HO-1 protein expression in NOD mice after CO treatment, suggesting that the beneficial effect of CO observed in present experimental setting is unlikely up-regulating HO-1 expression. Nevertheless, to completely rule out the implication of HO-1, additional experiments with condition of HO-1 activity inhibition or HO-1 deficiency in NOD mice will be needed. The detailed mechanism responsible for the protective effect of exogenous CO treatment on T1D remains to be determined. Further experiment demonstrated that the periodic CO treatment also prolonged the survival of NOD mice with chemical-induced overt diabetes. Together, these results suggest a possible role for CO in the protective function of HO-1 in NOD mice. 
